A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability,
pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with
advanced/metastatic hepatocellular carcinoma.